Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer

Keyphrases

• Breast Cancer Treatment 100%
• Structure-activity Relationship Studies 100%
• MDA-MB-231 100%
• ER-positive 100%
• Triple-negative Breast Cancer 100%
• Bax Activators 100%
• Antiproliferative Activity 50%
• Therapeutic Potential 50%
• Tumor Growth 50%
• Drug Candidates 50%
• Cell Apoptosis 50%
• IC50 Value 50%
• Nude Mice 50%
• In Vivo Efficacy 50%
• Side Chain 50%
• Bax Protein 50%
• MCF-7 Cancer Cell Line 50%
• Tumor Xenograft 50%
• Cytochrome c Release 50%
• Carbon Atom 50%
• 9H-fluorene 50%
• Mechanism of Action Studies 50%
• ER+ Breast Cancer 50%
• Nitro Group 50%
• Apoptotic Biomarkers 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Structure Activity Relationship 100%
• Breast Cancer 100%
• Triple Negative Breast Cancer 100%
• Malignant Neoplasm 33%
• Biological Marker 33%
• Tumor Growth 33%
• Neoplasm 33%
• Nude Mouse 33%
• Efficacy Study 33%
• Lead Compound 33%
• Antiproliferative Activity 33%
• IC50 33%
• Protein Bax 33%
• Cytochrome C 33%
• Fluorene 33%